One of the main risk factors that contribute to hyperlipidaemia is atherosclerosis and coronary heart disease. Therefore, researchers turn to synthesizing new compounds with potential lipid-lowering effects to overcome this issue. In the current study, Triton WR-1339 was used to induce hyperlipidaemia in the rat’s model. Moreover, we were able to synthesize, characterize, and validate a novel series of N-(4-benzoylphenyl) pyrrole-2-carboxamide derivatives; (compounds 3 and 5) and assess their potency as anti-hyperlipidemic agents. 300 mg/kg of triton WR-1339 was administered overnight intraperitoneally to fasted rats to urge hyperlipidemia and divided into five groups, control, hyperlipidemic, compounds 3-, 5-, and bezafibrate-treated rats. The pharmacological evaluation of compounds 3 and 5 at a dose of 15 mg/kg body weight showed that the elevated levels of plasma triglyceride, low-density lipoprotein cholesterol, and total cholesterol were significantly reduced after 18 hours of compounds 3 (p < 0.001) and compound 5 (p < 0.01) administration in comparison to the hyperlipidemic and control group at a given 15 mg/kg body weight dose. Moreover, it was noted that compounds 3 and 5 increased the high-density lipoproteins cholesterol levels significantly by 22% and 4.5% consecutively. Therefore, it can be concluded from these findings that N-(4-benzoylphenyl) pyrrole-2-carboxamide derivatives (3 and 5) have a definite antihyperlipidemic potential which could serve as protective agents against cardiovascular diseases and atherosclerosis.
Key words: Pyrrole carboxamides, hypolipidemic activity, Triton WR-1339, rats
|
